From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement
FROM THE EDITORS

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Charise Gleason Amy Pierre

Charise Gleason, MSN, NP-C, AOCNP
Winship Cancer Institute of Emory University
Nell Hodgson Woodruff School of Nursing at Emory Healthcare

Amy Pierre, MSN, RN, ANP-BC
Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division
Flatiron Health Real World Evidence Research Oncology

News & Literature Highlights

HemaSphere

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant

International Journal of Molecular Sciences

Breaking barriers: The role of the bone marrow microenvironment in multiple myeloma progression

Future Oncology

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

Clinical Lymphoma, Myeloma & Leukemia

Practical guidance on the clinical management of belantamab mafodotin for patients with relapsed/refractory multiple myeloma: Recommendations from the Middle East and North Africa expert panel

ASCO 2025

DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma: A subgroup analysis in patients with high-risk cytogenetic features

Frontiers in Oncology

Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: Results of a nurse survey

Blood

Are we ready for an MRD-driven approach in multiple myeloma?

Nature Cancer

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Journal of Clinical Oncology

Isatuximab subcutaneous by on-body delivery system vs isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Phase 3 IRAKLIA study

Current Obesity Reports

Unraveling obesity and multiple myeloma: Insights from epidemiology and molecular mechanisms

Advertisement
Advertisement